Trial Profile
A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Aspirin
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Feb 2019 Status changed from recruiting to discontinued.
- 09 Oct 2016 Status changed from not yet recruiting to recruiting.
- 27 Apr 2016 New trial record